SRR25617889
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.260
- PROTEIN_SECRETION+0.250
- HEME_METABOLISM+0.190
- OXIDATIVE_PHOSPHORYLATION+0.160
- ESTROGEN_RESPONSE_LATE+0.120
- PANCREAS_BETA_CELLS+0.100
- SPERMATOGENESIS+0.060
- ADIPOGENESIS+0.030
- BILE_ACID_METABOLISM+0.010
- ANDROGEN_RESPONSE-0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- INTERFERON_GAMMA_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.490
- TNFA_SIGNALING_VIA_NFKB-0.470
- COMPLEMENT-0.410
- IL6_JAK_STAT3_SIGNALING-0.410
- INFLAMMATORY_RESPONSE-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.370
- MYC_TARGETS_V2-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579848 | — | B | 0.945 |
| 2 | SRR29022828 | — | B | 0.901 |
| 3 | TCGA-E2-A15G-01A-11R-A12D-07 | — | B | 0.891 |
| 4 | MBCProject_0343_T1_RNA | — | B | 0.889 |
| 5 | SRR650196 | — | — | 0.884 |
| 6 | TCGA-A2-A4S0-01A-21R-A266-07 | — | B | 0.881 |
| 7 | TCGA-MP-A5C7-01A-11R-A262-07 | — | cohortA2 | 0.875 |
| 8 | TCGA-D8-A1XV-01A-11R-A14M-07 | — | B | 0.874 |
| 9 | aMVAC.P_016_TURBT_S236 | — | — | 0.872 |
| 10 | DRR168589 | — | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |